Affiliations of Cancer Center Physicians

<p>Aditya Juloori (C)</p> Signup and view all the answers

<p>Ankit Bharat (D)</p> Signup and view all the answers

<p>Patricio M. Polanco (B)</p> Signup and view all the answers

<p>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (B)</p> Signup and view all the answers

<p>Michael Lanuti (A)</p> Signup and view all the answers

<p>The University of Texas MD Anderson Cancer Center (B)</p> Signup and view all the answers

<p>Christine M. Lovly, MD, PhD (B)</p> Signup and view all the answers

<p>University of Wisconsin Carbone Cancer Center (B)</p> Signup and view all the answers

<p>University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute (A)</p> Signup and view all the answers

<p>Billy W. Loo, Jr., MD, PhD (B)</p> Signup and view all the answers

<p>Lucian R. Chirieac, MD (A)</p> Signup and view all the answers

<p>Abramson Cancer Center at the University of Pennsylvania (A)</p> Signup and view all the answers

<p>Christine M.Lovly, MD, PhD (A)</p> Signup and view all the answers

<p>NCCN emphasizes the importance of clinical trials and advocates for broad participation. (C)</p> Signup and view all the answers

<p>The guidelines cannot be reproduced in any form without express written permission from NCCN. (C)</p> Signup and view all the answers

<p>At <a href="http://www.nccn.org/patients">www.nccn.org/patients</a>. (C)</p> Signup and view all the answers

<p>Version 11.2024, October 15, 2024 (D)</p> Signup and view all the answers

<p>Gregory J. Riely, MD, PhD (C)</p> Signup and view all the answers

<p>UC San Diego Moores Cancer Center (C)</p> Signup and view all the answers

<p>Clinical trials should strive to involve a diverse range of participants. (C)</p> Signup and view all the answers

<p>Initial Evaluation and Clinical Stage (NSCL-1) (A)</p> Signup and view all the answers

<p>Category 2A (C)</p> Signup and view all the answers

<p>Stage IB (B)</p> Signup and view all the answers

<p>T1–2, N2 (D)</p> Signup and view all the answers

<p>Multiple Lung Cancers (N0–1) (A)</p> Signup and view all the answers

<p>Pleural or Pericardial Effusion (B)</p> Signup and view all the answers

<p>Stage IIIB (A)</p> Signup and view all the answers

<p>Stage IIIA (D)</p> Signup and view all the answers

<p>Surveillance After Completion of Definitive Therapy (NSCL-17) (B)</p> Signup and view all the answers

<p>Principles of Molecular and Biomarker Analysis (NSCL-H) (B)</p> Signup and view all the answers

<p>Systemic Therapy for Advanced or Metastatic Disease (NSCL-19) (C)</p> Signup and view all the answers

<p>Concurrent Chemoradiation Regimens (NSCL-F) (C)</p> Signup and view all the answers

<p>Emerging Biomarkers to Identify Novel Therapies for Patients with Metastatic NSCLC (NSCL-I) (D)</p> Signup and view all the answers

<p>The fundamental techniques and considerations in cancer surgery (A)</p> Signup and view all the answers

<p>Clinicians should use independent medical judgment when applying NCCN Guidelines, considering individual patient circumstances. (D)</p> Signup and view all the answers

<p>The guidelines, including illustrations, are copyrighted and require express written permission for reproduction. (B)</p> Signup and view all the answers

<p>Nivolumab 360 mg and platinum-based doublet chemotherapy can be given every 3 weeks for up to 3-4 cycles, with the option of single-agent nivolumab as adjuvant treatment after surgery. (A)</p> Signup and view all the answers

<p>Pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks for up to 1 year if there are no contraindications to immune checkpoint inhibitors. (B)</p> Signup and view all the answers

<p>Stage IIIB (T3, N2) (A)</p> Signup and view all the answers

<p>200 mg every 3 weeks or 400 mg every 6 weeks (B)</p> Signup and view all the answers

<p>Neither Pembrolizumab nor Atezolizumab are indicated, according to the content provided. (B)</p> Signup and view all the answers

<p>Up to 1 year (D)</p> Signup and view all the answers

<p>Updates to neoadjuvant systemic therapy for patients who are candidates for immune checkpoint inhibitors. (D)</p> Signup and view all the answers

<p>Neither Pembrolizumab nor Atezolizumab are indicated, according to the content provided. (B)</p> Signup and view all the answers

Standards for cancer treatment established by NCCN.

A common type of lung cancer that is less aggressive than small cell lung cancer.

Research studies involving patient volunteers to test new treatments.

Ensuring diverse patient representation in clinical trials.

Recruiting a wide range of participants in clinical trials.

Website providing NCCN Guidelines for patients.

Latest edition of NCCN Guidelines for Non-Small Cell Lung Cancer.

Official acknowledgment by NCCN for clinical importance.

A medical doctor affiliated with cancer research, likely involved in clinical studies.

A physician associated with cancer treatment and research at UCSF.

A doctor contributing to cancer research at UT Southwestern.

A comprehensive center for cancer research and treatment located in Utah.

A leading institution specializing in cancer treatment and research.

A physician specializing in thoracic conditions at Mass General.

A premier cancer treatment and research facility in Northwestern University.

A center dedicated to advanced cancer research and patient care.

A leading cancer treatment and research center located in Texas.

A cancer research and treatment center at the University of Michigan.

Cancer treatment and research facility affiliated with Stanford University in California.

An Ivy League university that houses a cancer center focusing on research and treatments.

A prominent cancer research and patient care center in Nashville, TN.

A Boston-based institution known for cancer care and research.

A renowned cancer treatment center located within the Cleveland Clinic.

An academic cancer center in Ohio that focuses on scientific research and treatment.

Stage IA is characterized by T1abc, N0 classification.

Stage IIB includes T3 invasion with N0 classification.

Stage IIIA involves T4 extension with N0–1, or T3 with N1.

Recommendations categorized, mainly 2A unless specified otherwise.

Stage IIIB features include T4, N2 or T3, N3 classification.

Stage IVA indicates M1a with pleural or pericardial effusion.

Presence of multiple lung cancers classified as N0 or N1.

Consensus suggests that most guidelines are appropriate.

Treatment given before surgery to shrink tumors, often using immunotherapy like nivolumab.

An immune checkpoint inhibitor used in cancer treatment, specifically in lung cancer.

Post-surgery treatment to eliminate any remaining cancer cells, such as continued nivolumab.

Another immune checkpoint inhibitor for treating certain stages of non-small cell lung cancer.

Genetic changes that can influence the treatment strategy for lung cancer patients.

Specific genetic alterations that can affect the treatment pathway for lung cancer.

Specific classifications of non-small cell lung cancer based on spread and severity.

A classification of non-small cell lung cancer indicating a significant risk of recurrence and need for aggressive treatment.

Primary treatment intended to eliminate cancer.

Treatment to target cancer throughout the body.

Combined use of chemotherapy and radiation therapy.

Study of specific molecules in cancer for targeted treatment.

Ongoing care and support for cancer survivors post-treatment.

Minimally invasive procedure using heat to destroy tumors.

New biological indicators for guiding treatment decisions.